CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-23 | Fairmount Funds Management LLC Director | Purchase | +454,545 | $22.00 | $10.0M | 3,914,458 |
| 2025-07-01 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2025-07-01 | Kiselak Tomas Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2025-07-01 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2025-07-01 | Ajer Jeffrey Robert Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2025-07-01 | Gheuens Sarah Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2025-07-01 | Moses Jennifer K. Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2025-06-10 | Fairmount Funds Management LLC Director | Option exercise | +12,500 | $12.31 | $154K | 3,459,913 |
| 2025-06-10 | Fairmount Funds Management LLC Director | Option exercise · Stock Option (Right to Buy) | −12,500 | 0 | ||
| 2025-06-09 | Fairmount Funds Management LLC Director | Option exercise | +1,600 | $7.80 | $12K | 3,447,413 |
| 2025-06-09 | Fairmount Funds Management LLC Director | Option exercise · Stock Option (Right to Buy) | −1,600 | 0 | ||
| 2025-04-07 | Ajer Jeffrey Robert Director | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2025-03-10 | Tripuraneni Radhika Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +310,700 | 310,700 | ||
| 2025-03-10 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +42,000 | 42,000 | ||
| 2025-03-03 | Tousignant Jennifer Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +124,072 | 124,072 | ||
| 2025-03-03 | Tousignant Jennifer Chief Legal Officer | Grant or award · Restricted Stock Units | +20,679 | 20,679 | ||
| 2025-03-03 | Mahoney Stephen F. President and CEO | Grant or award · Stock Option (Right to Buy) | +440,565 | 440,565 | ||
| 2025-03-03 | Mahoney Stephen F. President and CEO | Grant or award · Restricted Stock Units | +73,428 | 73,428 | ||
| 2025-03-03 | Beetham Thomas W. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +225,814 | 225,814 | ||
| 2025-03-03 | Beetham Thomas W. Chief Operating Officer | Grant or award · Restricted Stock Units | +37,636 | 37,636 |
Page 3 of 10 · 182 trades